Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford has conferred the title of Associate Professor to Yoel Lubell, Head of Economics and Translational Research at MORU, to Olivo Miotto from the Centre for Genomics and Global Health at MORU, and to Ronald Geskus from OUCRU. Louise Thwaites, Clinical Research Fellow at OUCRU, was appointed University Research Lecturer.

The University of Oxford has conferred the title of Associate Professor to Yoel Lubell, Head of Economics and Translational Research, to Olivo Miotto from the Centre for Genomics and Global Health, and to Ronald Geskus from OUCRU. Louise Thwaites, Clinical Research Fellow at OUCRU, our sister unit in Vietnam, was appointed University Research Lecturer.

Based in MORU's Mathematical/Economic Modelling (MAEMOD) Department in Bangkok, Thailand, Professor Yoel Lubell leads the Economics and Translational Research Group (ETRG). ETRG focuses on the evaluation of diagnostics, treatments and vaccines for malaria and other infectious diseases. These evaluations are pursued using a variety of approaches ranging from economic and epidemiological modelling through laboratory investigations to clinical trials and qualitative research. Our ultimate aim is to provide policy makers with pragmatic and context specific assessments of the impact of new interventions if implemented in routine care. Where relevant we strive to take a broader view of the costs and benefits of new interventions accounting for factors such as their indirect impact on disease transmission and antimicrobial resistance as well as how such interventions’ cost-effectiveness varies in different epidemiological and socio-economic contexts or due to factors such as patents and health workers’ acceptance.

Professor Olivo Miotto focuses on translating the massive quantities of data produced by sequencing thousands of genomes into meaningful knowledge about the epidemiology of Plasmodium falciparum. By analyzing hundreds of thousands of genomic variations in each blood sample, he studies the genetics of parasite populations in four continents, and identifies patterns of evolution associated to responses to drug pressure and other human interventions. Based at MORU in Bangkok, Olivo collaborates with many clinical research groups in malaria endemic regions, particularly in Southeast Asia, to study relationships between  response to clinical therapy and genetics of the disease-causing parasites in the patient. In the early stages, the focus is on immediate problems, such as discovering mutations causing resistance to current drugs, such as artemisinin. However, Olivo's longer-term perspective is to create tools that will identify patterns in thousands of accumulated genomic sequences, leading to a deep understanding of parasite evolution and, ultimately, to interventions that will win the struggle against the disease.

Similar stories

Researchers call for access to Ivermectin for young children

MORU Bangkok Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Evidence supports WHO recommendation for primaquine combined with ACTs to block Plasmodium falciparum transmission

MORU Bangkok Publication Research

Evidence from a new study, initiated by the Primaquine Roll Out Group and conducted at WWARN, supports the World Health Organization (WHO) recommendation for use of 0.25mg/kg dose of primaquine (PQ) combined with artemisinin-based combination therapies (ACT) to block Plasmodium falciparum transmission.

Indonesia’s decision to prioritise COVID-19 vaccination to citizens aged 18-59 years old questionable

MORU Bangkok

The Indonesian government policy to exclude the elderly in the first phase of the COVID-19 vaccination program could hinder the vaccine’s impact in lowering mortality rates. COVID-19 mortality rates in Indonesia, the highest in Southeast Asia, are dominated by those in the 60 years and above age bracket. In this article published in The Conversation, Kartika Saraswati and fellow DPhil students elaborate how, by prioritising vaccination for elderly, Indonesia may optimally reduce the hospital burden and COVID-19 deaths amidst a limited vaccine supply during the first vaccination phase.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

MORU Bangkok Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Susie Dunachie awarded flagship NIHR career development award

Awards & Appointments MORU Bangkok

Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!

The COVID-19 vaccine: do we know enough to end the pandemic?

MORU Bangkok Research

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.